Tryngolza wins CHMP backing for severe hypertriglyceridemia
IONS•The EMA’s CHMP recommended expanding Tryngolza approval to adults with severe hypertriglyceridemia and fasting triglycerides of at least 880 mg/dL; a European Commission decision is expected in the fourth quarter of 2026.
1. European recommendation
The EMA’s CHMP recommended expanding approval of Ionis Pharmaceuticals’ TRYNGOLZA to adults with severe hypertriglyceridemia and fasting triglycerides of at least 880 mg/dL. A final European Commission decision is expected in the fourth quarter of 2026, ahead of the previously anticipated timeline.
